KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer

被引:11
|
作者
Sullivan, I. [1 ]
Salazar, J. [2 ,3 ]
Arqueros, C. [1 ]
Andres, M. [1 ]
Sebio, A. [1 ]
Majem, M. [1 ]
Szafranska, J. [4 ]
Martinez, E. [5 ]
Paez, D. [1 ]
Lopez-Pousa, A. [1 ]
Baiget, M. [2 ,3 ]
Barnadas, A. [1 ,6 ]
机构
[1] Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain
[2] Hosp Santa Creu & Sant Pau, Genet Dept, St Antoni Maria Claret 167, Barcelona 08025, Spain
[3] CIBERER, U 705, Barcelona, Spain
[4] Hosp Santa Creu & Sant Pau, Pathol Dept, Barcelona, Spain
[5] Hosp Santa Creu & Sant Pau, Thorac Surg Dept, Barcelona, Spain
[6] UAB, Barcelona, Spain
来源
CLINICAL & TRANSLATIONAL ONCOLOGY | 2017年 / 19卷 / 07期
关键词
Resectable non-small cell lung cancer; Prognostic marker; VEGF pathway; KRAS; Genetic variants; ENDOTHELIAL GROWTH-FACTOR; PHARMACOGENETIC FACTORS; PATHWAY POLYMORPHISMS; VEGF POLYMORPHISMS; EXPRESSION; SURVIVAL; ANGIOGENESIS; CHEMOTHERAPY; ASSOCIATION; BEVACIZUMAB;
D O I
10.1007/s12094-017-1620-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Several angiogenic prognostic markers are under investigation because of their potential clinical utility, aiming to improve patient outcomes. We hypothesized that genetic variant in the VEGF pathway could be used as prognostic markers of survival in non-small cell lung cancer (NSCLC) patients undergoing pulmonary resection. Methods We evaluated the relationship between genetic variants in the VEGF pathway and relapse-free survival (RFS, main endpoint) and overall survival (OS, secondary endpoint) among 131 patients with stage I-III NSCLC treated with surgical resection from 2009 to 2013. Clinical, pathological and surgical data were prospectively collected. Twenty-five variants in sixteen relevant genes were selected and genotyped in tumor samples by real time PCR. The Kaplan-Meier method with the log-rank test and Cox's regression models were used for RFS and OS analyses. Results With a median follow-up of 36 (min = 2.8; max = 67.4) months, there were 31 (24%) relapses and 31 (24%) deaths. Overall, median RFS was not reached and median OS was 65 [95% confidence interval (CI) 56-75] months. The KRAS rs1137282 and PIK3C2A rs4356203 variants were significantly associated with RFS. For KRAS rs1137282, the 3-year RFS was 76% [95% CI 64-84%] in patients harboring an A/A genotype compared to 53% [95% CI 37-69%] in patients harboring an A/G or G/G genotype (p = 0.02). For PIK3C2A rs4356203, patients with an A/A or an A/G genotype had a 3-year RFS of 72% [95% CI 58-76%], whereas in patients with a G/G genotype was 49% [95% CI 28-70%] (p = 0.02). These associations remained statistically significant after adjusting for all the relevant clinical parameters in the multivariable analysis. Conclusion Genetic variants in VEGF pathway may be associated with recurrence in stage I-III NSCLC. Specifically, the KRAS rs1137282 could be considered as a prognostic factor for recurrence in resectable NSCLC patients. Although PIK3C2A rs4356203 was associated with RFS, further analyses are necessary to confirm these data.
引用
收藏
页码:884 / 890
页数:7
相关论文
共 50 条
  • [41] Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
    Tomasini, Pascale
    Walia, Preet
    Labbe, Catherine
    Jao, Kevin
    Leighl, Natasha B.
    ONCOLOGIST, 2016, 21 (12): : 1450 - 1460
  • [42] Prognostic Factors for Patients With KRAS Mutated Non-Small Cell Lung Cancer and Brain Metastases
    Tsakonas, G.
    Skribek, M.
    Kamali, C.
    Zerdes, I.
    Johannsdottir, B.
    Ekman, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S599 - S599
  • [43] The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer
    Nygaard, Anneli Dowler
    Spindler, Karen-Lise Garm
    Pallisgaard, Niels
    Andersen, Rikke Fredslund
    Jakobsen, Anders
    LUNG CANCER, 2013, 79 (03) : 312 - 317
  • [44] Tumor Engraftment is Prognostic for Disease Recurrence in Resected Non-Small Cell Lung Cancer
    Patel, B. G.
    Pepin, K.
    Li, S.
    Davies, S. R.
    Rohatgi, A.
    Herzog, B.
    Ward, J. P.
    Baggstrom, M.
    Waqar, S.
    Morgensztern, D.
    Govindan, R.
    Devarakonda, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E22 - E22
  • [45] Prognostic factors before and after recurrence of resected non-small cell lung cancer
    Baba, Tetsuro
    Uramoto, Hidetaka
    Takenaka, Masaru
    Chikaishi, Yasuhiro
    Oka, Soichi
    Shigematsu, Yoshiki
    Hanagiri, Takeshi
    Tanaka, Fumihiro
    RESPIRATORY INVESTIGATION, 2012, 50 (04) : 151 - 156
  • [46] Prognostic models of recurrence-free survival in non-small cell lung cancer
    Palmer, K. R.
    Houston, A.
    Macpherson, H.
    Wang, W.
    Quartly, F.
    Grant, M.
    Patel, K. R.
    Ghose, A.
    Williams, S.
    Farah, L. Lim
    Conibear, J.
    Giaslakiotis, K.
    Lau, K.
    Ricketts, W.
    Januszewski, A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S92 - S92
  • [47] Prognostic factors for nivolumab monotherapy in postoperative recurrence of non-small cell lung cancer
    Inoue, Takashi
    Ishihama, Hiromi
    Tachibana, Taimei
    Imamura, Nobuhiro
    Nonaka, Yuuto
    Ito, Yoshiyuki
    Araki, Osamu
    Sumiko, Maeda
    Chida, Masayuki
    ANNALS OF ONCOLOGY, 2021, 32 : S334 - S334
  • [48] Prognostic factors for recurrence in patients with surgically resected non-small cell lung cancer
    Satoh, Hiroaki
    Iguchi, Kesato
    Nakamura, Ryota
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2022, 26 (04): : 314 - 314
  • [49] Prognostic factors for recurrence in patients with surgically resected non-small cell lung cancer
    Moskalenko, Yuliia
    Smorodska, Olga
    Deineka, Volodymyr
    Kravets, Oleksandr
    Moskalenko, Roman
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2022, 26 (03): : 239 - 246
  • [50] Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer
    Perez-Ramirez, Cristina
    Canadas-Garre, Marisa
    Alnatsha, Ahmed
    Angel Molina, Miguel
    Robles, Ana I.
    Villar, Eduardo
    Ramon Delgado, Juan
    Jose Faus-Dader, Maria
    Angel Calleja-Hernandez, Miguel
    SURGICAL ONCOLOGY-OXFORD, 2017, 26 (03): : 278 - 285